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sults There was no signiﬁcant difference between the 3 groups in
the occurrence of FN or documented infection. However, hyper-
glycemia was signiﬁcantly associated with organ dysfunction and
aGVHD. OS was better and TRM was less in group1 compared
with group2 and group3. Conclusion Degrees of hyperglycemia
during neutropenia was associated with an increased risk of organ
dysfunction and aGVHD, which further led to higher TRM and
lower OS. These results support the possibility that intensive
glucose control reduces morbidity and mortality after HSCT.
blood glucose level
normoglycemia
(n28)
mild
hyperglycemia
(n49)
moderate and
severe
hyperglycemia
(n14)
FN 25 (89%) 43 (88%) 13 (93%)
Documented infection 9 (32%) 10 (20%) 6 (43%)
hypercreatininemia (serum
creatinine>2mg/dl or
more than twice of
baseline) 1 (4%) 4 (8%) 4 (29%)
hyperbilirubinemia (serum
bilirubin>2 mg/dl) 3 (11%) 11 (22%) 6 (43%)
CRP elevation (serum
CRP>15 mg/dl) 4 (14%) 15 (31%) 9 (64%)
aGVHD (II-IV) 4 (14%) 18 (38%) 7 (58%)
OS (1-year) 87% 70% 56%
TRM (1-year) 5% 17% 30%
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Bitencourt, M.A.1, Coutinho, E.N.1, Setubal, D.C.1, Zanis-Neto, J.1,
de Medeiros, C.P.1, Pasquini, R.1 1Hospital de Clinicas - Universidade
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INTRODUCTION: Thrombotic microangiopathy is a rare
complication after HSCT. Given the different pathophisiology of
the disease and high mortality observed, our purpose is evaluating
clinical carcteristcs of these patients and risk factors for survival.
PATIENTS AND METHODS: From 1991to 2004, 1066
HSCT were performed at HC-UFPR (Curitiba, Brazil). We iden-
tiﬁed in our database 17 patients with the diagnosis of thrombotic
microangiopathy (prevalence of 1.6%). M4/F13, Median
age(y)11; Diagnosis included: SAA: 2; Fanconi anemia: 4; Acute
leukemias: 7, Others 2.
Conditioning regimen consisted of BUCY in 9/17 (52%); CI 
TBI in 3/17 (18%) of the patients, NMA regimens in 18% and
others in 12% of the patients. Immunephrophylaxis
consisted of CSA and MTX in 52% of the patients.Twelve
patients received related and ﬁve received unrelated donor trans-
plant.
Marrow was the stem cell source in all but one patient who
received cord blood.
Twelve patients were HLA identical, three patients had a class
one mismatch, one patients had a class II mismatch and one patient
had more than one mismatch.
Median number of cells infused were 2,57  108/KG.
RESULTS A-GVHD grade II-IV was present in 12 (70%) pa-
tients and extensive C-GVHD was present in only 18% of the
patients. Median survival was 99 days and estimated overall survival
in 25 years is only 15%, despite therapy. Infection was present in
all but one patient (94%). Ten patients had serious bacterial in-
fections (58%), eight of them by gram-positive bacteria. Fungal
infection was identiﬁed in ﬁve patients (2 Candida sp and 3 As-
pergillus sp). Viral infection was identiﬁed in 12 patients (eight of
them with CMV positive antigenemia). Causes of death included:
A-GVHD in four pt, C-GVHD in 2 patients, infection in 6
patients, bleeding in two patients and persistent disease in one
patient. The only signiﬁcant factor for survival was severe mucosi-
tis (more than grade II).
CONCLUSION: 1. OS was extremely low (15%) despite ther-
apy; 2. Infection ( specially gram-positive bacterial infections and
CMV positive antigenemia) was present at the majority of the
patients and was the main cause of death; 3. A-GVHD was present
in 52% of the patients; 4. Severe mucositis was associated to a
lower survival rate (p0,02).
237
LONG TERM RESULTS OF ALLOGENEIC STEM CELL TRANSPLANT FOR
CML IN PEDIATRIC PATIENTS: A STUDY OF 50 CASES TRANSPLANTED
OVER 20 YEARS IN A SINGLE INSTITUTION
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Azambuja, A.P.1, Medeiros, L.1, Setubal, D.C.1, Bitencourt, M.A.1,
Oliveira, M.M.1, Coutinho, E.N.1, Zanis-neto, J.1, de Medeiros, C.P.1,
Pasquini, R.1 1Hospital de Clinicas - Universidade Federal do Parana,
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Introduction: Chronic myeloid leukemia (CML) accounts for
2-3% of the leukemias in childhood. The only potential curative
treatment is allogeneic hematopoietic stem cell transplantation
(HSCT), although promising results achieved with imatinib me-
sylate in adults substantiate its use as a therapeutic alternative for
children. The aim of this study is to analyze the outcomes of
HSCT in pediatric patients regarding overall survival (OS) and
main causes of death.
Materials and methods: Retrospective analysis of children aged
1-17 years, diagnosed with CML who underwent HSCT in a single
institution in Brazil between jan/1984 and aug/2005. Survival was
estimated by Kaplan-Meier curves. Log Rank test was used for
comparison of continuous variables.
Results: Fifty patients were assessed, 31 male and 19 female.
Median age of 13,5 years (1-17). Forty one patients (82%) were in
ﬁrst chronic phase (CP1) and 9 in advanced phases. The interval
between diagnosis and HSCT had a median time of 17,5 months
(5-84). The source of stem cells was bone marrow in 44 patients
(88%), umbilical cord blood in 5 (10%) and peripheral blood stem
cell in 1 (2%). Thirty nine patients (78%) underwent related
HSCT and 11 (22%) unrelated donor HSCT. Conditioning reg-
imens: busulfan and cyclophosphamide in 35 patients (70%) and
TBI containing regimens in 15 (30%). Complete engraftment
occurred in 82% of the transplants. Acute (a) graft-versus-host-
disease (GVHD) grades II-IV occurred in 44% of the patients,
with 20% grade IV. Extensive chronic (c) GVHD occurred in
15/40 patients (38%). Fifteen patients (32%) relapsed after HSCT.
Mortality in the study population was 48% and the main causes of
death were: relapse in 6 patients (25%), a-GVHD in 6 (25%) and
c-GVHD in 4 (17%). Estimated OS in 20 years was 50%, with a
median survival of 1926 days. When analyzed separately, patients
in CP1 who received related HSCT and immuneprophilaxis with
three drugs (steroids, cyclosporine and methotrexate) had an esti-
mated OS in 20 years of 70%.
Conclusions: 1) Long term follow up of these children with
CML who underwent allogeneic HSCT demonstrate an OS of
50%, reaching 70% in low risk patients. 2) Main causes of death
were relapse, acute and chronic GVHD.
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RISK FACTOR ANALISIS FOR SURVIVAL IN 125 UNRELATED TRANS-
PLANTS FOR MALIGNANT DISEASES PERFORMED OVER TEN YEARS IN
A SINGLE CENTER IN BRAZIL
Funke, V.A.M.1, Coutinho, E.N.1, Setubal, D.C.1, Ruiz, J.1,
Bonﬁm, C.M.1, Bittencourt, M.A.1, Oliveira, M.M.1, Zanis-Neto, J.1,
de Medeiros, C.P.1, Pasquini, R.1 1Hospital de Clinicas - Universidade
Federal do Parana, Curitiba, PR, Brazil.
INTRODUCTION: Unrelated transplants are incresingly used
for therapy of malignant diseases. The objective of this study is
evaluating risk factors for overall survival among 125 unrelated
transplants performed at the BMT center of HC-UFPR in Cu-
ritiba, Brazil.
PATIENTS AND METHODS: we analyzed results of unre-
lated HSCT performed from 07/95 to 06/05.Kaplan Meier was
used to estimate overall survival. Log rank test was used to compare
survival curves and Fisher’s exact test for comparison of categoric
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